Literature DB >> 11898885

Pharmaceutical considerations in aerosol drug delivery.

Robert J Kuhn1.   

Abstract

Aerosolized drug delivery has been used for over 50 years, but its quality and scope continue to increase. Three factors affect this form of drug delivery: the nebulizer, the compressor, and the actual drug preparation. As technology and knowledge improve, this delivery system also improves. Patients with cystic fibrosis, in particular, can benefit significantly from this form of therapy.

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 11898885     DOI： 10.1592/phco.22.6.80s.33907

Source DB:  PubMed          Journal:  Pharmacotherapy        ISSN： 0277-0008            Impact factor:   4.705


  7 in total

Review 1.  Inhaled Antibiotics for Gram-Negative Respiratory Infections.

Authors:  Eric Wenzler; Dustin R Fraidenburg; Tonya Scardina; Larry H Danziger
Journal:  Clin Microbiol Rev       Date:  2016-07       Impact factor: 26.132

2.  Elevated tobramycin concentrations following endotracheal administration in a premature infant.

Authors:  Amanda Howard-Thompson; Michael L Christensen
Journal:  J Pediatr Pharmacol Ther       Date:  2008-04

3.  Aerosolized Delivery of Antifungal Agents.

Authors:  Jennifer Le; Daryl S Schiller
Journal:  Curr Fungal Infect Rep       Date:  2010-04-13

Review 4.  Inhaled therapeutics for prevention and treatment of pneumonia.

Authors:  Amar Safdar; Samuel A Shelburne; Scott E Evans; Burton F Dickey
Journal:  Expert Opin Drug Saf       Date:  2009-07       Impact factor: 4.250

5.  Characterization of a reverse-phase perfluorocarbon emulsion for the pulmonary delivery of tobramycin.

Authors:  Ryan A Orizondo; Charlene Irvin Babcock; Mario L Fabiilli; Leonid Pavlovsky; J Brian Fowlkes; John G Younger; Keith E Cook
Journal:  J Aerosol Med Pulm Drug Deliv       Date:  2014-01-29       Impact factor: 2.849

6.  [Nebulization of emergency medications in the south German rescue service].

Authors:  M Otto; Y Kropp; T Viergutz; M Thiel; C Tsagogiorgas
Journal:  Anaesthesist       Date:  2021-06-22       Impact factor: 1.052

7.  Inhalationally Administered Semifluorinated Alkanes (SFAs) as Drug Carriers in an Experimental Model of Acute Respiratory Distress Syndrome.

Authors:  Matthias Otto; Jörg Krebs; Peter Welker; René Holm; Manfred Thiel; Luciano Gattinoni; Michael Quintel; Charalambos Tsagogiorgas
Journal:  Pharmaceutics       Date:  2021-03-23       Impact factor: 6.321
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.